VIRX — Viracta Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $32.53m
- $9.56m
Annual cashflow statement for Viracta Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -23.3 | -21.6 | -115 | -49.2 | -51.1 |
| Depreciation | |||||
| Non-Cash Items | 1.79 | 0.488 | 94.1 | 12.9 | 5.59 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.65 | -0.317 | 1.68 | 0.608 | 5.08 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -22.2 | -21.4 | -18.9 | -35.5 | -39.9 |
| Capital Expenditures | — | — | -0.252 | -0.045 | -0.138 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -16.3 | 16.4 | 13.1 | -53.8 | 15.1 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -16.3 | 16.4 | 12.9 | -53.9 | 15 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 43 | 7.18 | 62.4 | 22.5 | 0.438 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.57 | 2.15 | 56.5 | -66.8 | -24.5 |